Skip to main content

FARAPULSE™

Pulsed Field Ablation System*

play icon
Farapulse Pulsed Field Ablation System Animation
FARAWAVE™ Pulsed Field Ablation Catheter
FARAPULSE™ Pulsed Field Ablation System
play icon
Farapulse Pulsed Field Ablation System Animation
FARAWAVE™ Pulsed Field Ablation Catheter
FARAPULSE™ Pulsed Field Ablation System
FARAPULSE Pulsed Field Ablation System Animation
FARAWAVE™ Pulsed Field Ablation Catheter
FARAPULSE™ Pulsed Field Ablation System

Learn more about pulsed field ablation (PFA) and future ablation technologies such as the FARAPULSETM Pulsed Field Ablation System. The design goals of FARAPULSE:

  • Preferentially ablate myocardium to reduce risk of collateral structure damage
  • Deliver durable transmural pulmonary vein (PV) lesions to limit redo procedures for PV triggers
  • Address variable patient PV anatomy for reproducible procedures and limit LA dwell time
  • Minimize system components and user-interface adjustments to simplify the procedure and shorten the learning curve

Key Resources

Learn more about PFA Clinical data Clinical compendium
Sign up for newsletter
*CAUTION: Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for sale. Product not FDA approved. Not approved for sale in the US. For educational purposes only.
 

Stay up to date on the latest data

Mounting clinical data ranging from esophageal safety to PVI durability is available on the emerging new therapy of pulsed field ablation and the FARAPULSE PFA System.
See clinical data
 

Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT and PEFCAT II1

0%
AE Fistulas, Phrenic Nerve Damage, PV Stenosis1
96%
PVs isolated at ~3 months1†
85 ± 5%
Kaplan-Meier estimated freedom from atrial arrhythmias at 1 year1†
 

Understanding a different mechanism of action

PFA Science and Tissue Labeled Illustration
PFA Science and Tissue Labeled Illustration
Pulsed Field Ablation (PFA) uses a non-thermal energy source that spares collateral tissues while preferentially targeting myocardium.2
Understand PFA
 

FARAPULSE™ PFA System designed and optimized for PFA

FARADRIVE
FARADRIVE
FARADRIVE

The FARAPULSE™ PFA System was specifically built from the ground-up to optimize cardiac PFA therapy with an added design goal of a simplified user experience. 

The FARAPULSE PFA System comprises three main components:

  • FARADRIVE™ Steerable Sheath designed for access and navigation
  • FARAWAVE™ PFA Catheter designed to treat a range of PV anatomies using an over-the-wire catheter with variable distal shapes (basket and flower)
  • FARASTAR™ PFA Generator designed for an easy three-button click to PREPARE, CONFIRM and DELIVER therapy using bipolar & biphasic waveforms with proprietary pulses
 
Chun quote
 

Dedicated history to cardiac PFA

Since its inception, we’ve continued to define, optimize, and validate pulsed field ablation therapy with design goals of patient safety and physician expectations. Following CE Mark of the system, nearly 2,000 patients in 9 countries were successfully treated in 2021 as reported in a retrospective survey, the MANIFEST-PF publication. Several publications and trials have evaluated or continue to evaluate the clinical safety and efficacy of the FARAPULSE PFA System, including the US ADVENT IDE clinical study which began in 2021 and completed enrollment in 2022.
FARASTAR
The FARAPULSE PFA System represents a validated PFA with the design history, peer-reviewed synopsis and, clinical data to support it.
 
Top